PYLARIFY® Imaging Site Locator


For information about ordering PYLARIFY® for your imaging site, and how to get started, contact PYLARIFY®

Customer Support at 1-8‌‌00-9‌6‌4-04461-8‌00-9‌64-0446 M-F 8:30 am-8:00 pm EST, or email cspyl@lantheus.com.

Please enter your ZIP code to locate the nearest imaging site that offers PYLARIFY®.

Please enter a valid ZIP Code

This may not be a comprehensive list. The sites listed are provided as an informational resource only.

Progenics does not warrant, whether expressed or implied, that the Locator is accurate or complete. Progenics does not recommend or endorse any site included in the Locator for any purpose. It is your responsibility to select a site and you assume full responsibility for your interactions with any site you contact through the Locator. Progenics is not responsible for the medical care or advice given by any site you choose to contact.

This free service provides a list of sites that may be qualified to provide PYLARIFY® imaging. These sites do not pay a fee to be listed in the PYLARIFY® Imaging Site Locator (“Locator”), and their participation does not impose any requirements on the manner in which they treat or provide services to patients. Participating sites are listed based on the geographical search information entered. Some of the participating sites may have other financial relationships with Progenics as recipients of research grants or other similar payments.

Sites may request to be removed from the Locator and Progenics retains the right to remove sites from the Locator.

To remove your facility from this list or request a specific change/update to a current site already in the Locator, contact us at pylcenters@lantheus.com.

INDICATION

PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Reference

  1. FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.